186 related articles for article (PubMed ID: 25627335)
1. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
3. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
Roman MW; Wilkinson SM
Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751
[TBL] [Abstract][Full Text] [Related]
5. Levomilnacipran and Vortioxetine for Adults with Major Depressive Disorder.
Scarff JR
J S C Med Assoc; 2015 Dec-2016 Jan; 111(4):131-3. PubMed ID: 27141705
[No Abstract] [Full Text] [Related]
6. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of major depression in late life: what is the role of new agents?
Patel K; Abdool PS; Rajji TK; Mulsant BH
Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine hydrobromide, crofelemer, and teduglutide.
Hussar DA; Lye A
J Am Pharm Assoc (2003); 2014; 54(1):91-4. PubMed ID: 24407747
[No Abstract] [Full Text] [Related]
9. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
[No Abstract] [Full Text] [Related]
12. Vortioxetine for the treatment of major depression.
Dhir A
Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine: a review of its use in major depressive disorder.
Garnock-Jones KP
CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
Bundgaard C; Eneberg E; Sánchez C
Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
[TBL] [Abstract][Full Text] [Related]
16. Vilazodone: a review in major depressive disorder in adults.
McCormack PL
Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
[TBL] [Abstract][Full Text] [Related]
17. Vilazodone approved for major depression.
Traynor K
Am J Health Syst Pharm; 2011 Mar; 68(5):366. PubMed ID: 21330672
[No Abstract] [Full Text] [Related]
18. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
Al-Sukhni M; Maruschak NA; McIntyre RS
Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
[TBL] [Abstract][Full Text] [Related]
19. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]